News
The latest insights, sector developments and case updates from Potter Clarkson. Explore up-to-date content from our experts and stay informed on the issues shaping the IP landscape.
The latest insights, sector developments and case updates from Potter Clarkson. Explore up-to-date content from our experts and stay informed on the issues shaping the IP landscape.

Businesses operating in Asian markets often overlook a key form of intellectual property protection – utility models. Here, we explain how to secure maximum value from these advantageous rights that are currently under-utilised by non-Asian organisations.

The referring Court has withdrawn its request for a preliminary ruling by the Court of Justice of the European Union (CJEU) on the interpretation of Art. 3(c) of the Regulation on Supplementary Protection Certificates (SPCs) relating to Novartis’ attempts to obtain more than one SPC for its antibody product canakinumab.
%20now%20available%20for%20EUIPO%20design%20registrations.jpg)
The Digital Access Service (DAS) is a database for priority documents established and administered by the World Intellectual Property Office (WIPO).

With the withdrawal agreement ratified in late 2019, the UK formally left the European Union on 31 January 2020, entering an additional 11 month transition period.

In 2019, the IP community was captivated by a High Court judgment which told the unique story of how a Florida inventor, Mr Berardi, developed a new, expandable garden hose in his back garden, which he later patented.

In a recent judgment surrounding ophthalmic pharmaceutical product manufacturer Santen, the Court of Justice of the European Union (CJEU) has further limited opportunities for pharmaceutical companies to obtain Supplementary Protection Certificates (SPCs) for new applications of old products.

In a recent decision (BL O/321/20), the UK Intellectual Property Office (UKIPO) considered the interplay between the different incentives available under EU law for research into the paediatric use of new medicinal products.

After considering the case of two prominent bicycle designs, the Court of Justice of the European Union (CJEU) has judged copyright protection may apply to a product whose shape serves a technical function.

In a case concerning genetically modified mice that are engineered to produce a range of hybrid human/mouse antibodies, the multinational biotech company Regeneron sued Cambridge company Kymab for patent infringement.

The Court of Justice of the EU (CJEU) has handed down its judgment in Royalty Pharma (C-650/17) on the interpretation of Art. 3(a) of the EU’s Regulation on Supplementary Protection Certificates (SPCs).

In a case brought by established travel agency, Trailfinders, the High Court has for the first time considered the application of the so-called Trade Secrets Directive, which was implemented into UK law in June 2018.

On Wednesday, the Intellectual Property Enterprise Court handed down one of its first judgments of 2020 in the case of Response Clothing Limited (“Response”) v Edinburgh Woollen Mill Limited (“EWM”) (IP-2017-000174).

The rules governing the appeals process at the European Patent Office are being changed, with the aim being to speed up the appeals process and the expected effect being to reduce flexibility for appellants.

At the global level, the UKIPO study finds that almost 30,000 AI patent applications were published in 2017 - an increase of over 400% compared with 2007. These headline figures are dominated by AI patent applications published in the United States and China, as shown in the following figure. For comparison, this figure also shows AI patent applications published by a selection of other intellectual property offices considered in the UKIPO study.

Supplementary protection certificates (SPCs) compensate for delay to market entry for products (medicinal or plant protection) in the European Union (EU) and some European Economic Area (EEA) states by providing up to an additional five years of protection beyond patent expiry.

Earlier this week, the Supreme Court handed down its judgment in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, holding Warner-Lambert’s patent to be invalid, and that had key patent claims been valid, they would not have been infringed by Actavis.